[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356653-105":59,"doc-detail-356653-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrating-pik3ca-testing-into-clinical-practice-for-advanced-hrher2-breast-cancer-an-expert-consensus","Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer - An Expert Consensus","","Alterations in the PI3K/AKT/mTOR signaling pathway drive resistance to endocrine therapy in advanced HR+/HER2- breast cancer, making identification of activating PIK3CA mutations clinically actionable. A multidisciplinary panel of Italian experts used a structured consensus process to produce shared recommendations for molecular testing of PIK3CA, covering preanalytical, analytical, and clinical-therapeutic concerns. Twenty-three of twenty-nine statements reached complete agreement, defining sample selection, methods, sensitivity thresholds, reporting, interpretation, and integration of results.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrating-pik3ca-testing-into-clinical-practice-for-advanced-hrher2-breast-cancer-an-expert-consensus/356653/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrating-pik3ca-testing-into-clinical-practice-for-advanced-hrher2-breast-cancer-an-expert-consensus/356653.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PIK3CA testing important in advanced HR+/HER2- breast cancer?","Question",{"text":112,"@type":113},"Activating PIK3CA mutations have gained therapeutic relevance because PI3K/AKT/mTOR pathway alterations can mediate resistance to endocrine therapy. Identifying PIK3CA alterations supports use of PIK3CA-targeted inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the expert consensus panel focus on when developing testing recommendations?",{"text":117,"@type":113},"The panel addressed molecular testing of PIK3CA across preanalytical, analytical, and clinical-therapeutic areas, including sample selection, analytical methodologies, sensitivity thresholds, and guidance on result reporting and interpretation.",{"name":119,"@type":110,"acceptedAnswer":120},"What level of agreement was achieved among the consensus statements?",{"text":121,"@type":113},"Twenty-three out of twenty-nine statements reached complete agreement, corresponding to 100%. The recommendations also include guidance for non-canonical gene variants and other PI3K/AKT/mTOR pathway genes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356653,1790267296,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","The Breast 87 (2026) 104786  \nContents lists available at ScienceDirect  \nThe Breast  \njournal [homepage:](homepage: www.journals.elsevier.com/the-breast)[ www.journals.elsevier.com/the-breast](homepage: www.journals.elsevier.com/the-breast)  \nIntegrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2-  Breast Cancer: An Expert Consensus  \nCarmine De Angelisa,b,*,1, Dario de Biasec,d,1 , Lorenzo Gerratanae,f,1, Grazia Arpinog,h, Giampaolo Bianchinii,j , Isabella Castellanok,l, Giuseppe Curiglianom,n ,  \nLucia Del Mastroo,p , Alessandra Fabiq, Nicola Fuscor,n, Alessandra Gennaris,t,  \nValentina Guarneri u,v, Claudio Zamagni w, Alberto Zambellix,y , Umberto Malapellez,1,  \nFabio Puglisi e,f,1   \na Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS – Fondazione G. Pascale, Via Mariano Semmola, 52, Napoli 80131, Italy b Clinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy  \nc Solid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy d Department of Pharmacy and Biotechnology (FaBit), University of Bologna, Bologna, Italy  \ne Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), National Cancer Institute, IRCCS, Aviano, Italy f Department of Medicine, University of Udine, Udine, Italy  \ng Dipartimento di Medicina Clinica e Chirurgia Federico II, Naples, Italy  \nh Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, USA i Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy  \nj Universit`a Vita-Salute San Raffaele, Milan, Italy  \nk Pathology Unit, Department of Medical Sciences, City of Health, Turin, Italy l Science University Hospital, University of Turin, Turin, Italy  \nm European Institute of Oncology, IRCCS, Milan, Italy  \nn Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy  \no IRCSS Ospedale Policlinico San Martino, UO Clinica Oncologia Medica, Genoa, Italy  \np Department of Internal Medicine and Medical Specialties (DIMI), Universit`a di Genova, Genoa, Italy q Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy r Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy  \ns Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy t Division of Medical Oncology, Maggiore University Hospital, Novara, Italy u Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy  \nv Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy w IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy  \nx Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy  \ny Department of Medicine and Surgery, Universit`a Degli Studi di Milano Bicocca, Milan, Italy z Department of Public Health, University Federico II of Naples, Naples, Italy  \nA R T I C L E I N F O  \nKeywords:  \nHR+/HER2 − breast cancer PIK3CA  \nLiquid biopsy  \nNGS  \nExpert consensus  \nA B S T R A C T  \nBackground: Alterations in the PI3K/AKT/mTOR signaling pathway represent a mechanism of resistance to endocrine therapy in advanced HR+/HER2-breast cancer. The identification of activating mutations in PIK3CA has gained therapeutic relevance, guiding the use of PIK3CA-targeted inhibitors such as alpelisib and inavolisib. Methods: A multidisciplinary panel of Italian experts conducted a structured consensus process to develop shared recommendations for molecular testing of PIK3CA in advanced HR+/HER2-breast cancer, addressing preanalytical, analytical, and clinical-therapeutic areas of concern.  \nResults: A total of 23 out of 29 statements reached complete agreement (100%). The resulting recommendations encompass sample selection, analytical methodologies, sensitivity thresholds, result reporting, and clinical interpretation and integration. Additional guidance is provided for the management of non-canonical gene variants","cbCaim1zQdM934CM","https://ap.wps.com/l/cbCaim1zQdM934CM","pdf",1165534,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Abbreviations","[{\"question\":\"Why is PIK3CA testing important in advanced HR+/HER2- breast cancer?\",\"answer\":\"Activating PIK3CA mutations have gained therapeutic relevance because PI3K/AKT/mTOR pathway alterations can mediate resistance to endocrine therapy. Identifying PIK3CA alterations supports use of PIK3CA-targeted inhibitors.\"},{\"question\":\"What did the expert consensus panel focus on when developing testing recommendations?\",\"answer\":\"The panel addressed molecular testing of PIK3CA across preanalytical, analytical, and clinical-therapeutic areas, including sample selection, analytical methodologies, sensitivity thresholds, and guidance on result reporting and interpretation.\"},{\"question\":\"What level of agreement was achieved among the consensus statements?\",\"answer\":\"Twenty-three out of twenty-nine statements reached complete agreement, corresponding to 100%. The recommendations also include guidance for non-canonical gene variants and other PI3K/AKT/mTOR pathway genes.\"}]","Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer - An Expert Consensus | PDF",1790126600,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e1ed40d443cacbeea1fc1401e1863b4.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d98180251b5b1ca1c47777c44d55ea00.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b4041f5b13cc4ead67c62b9e0e918e1.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6713f8c7e475ffa6f823b2d52eb83f84.webp",980,1306]